Market Cap
Rp1.5t
Last Updated
2021/05/10 17:29 UTC
Data Sources
Company Financials
Executive Summary
PT Merck Tbk manufactures and sells pharmaceutical products in Indonesia. More Details
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet and slightly overvalued.
Share Price & News
How has Merck's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MERK is less volatile than 75% of ID stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: MERK's weekly volatility (3%) has been stable over the past year.
Market Performance
7 Day Return
-0.9%
MERK
1.3%
ID Pharmaceuticals
-0.5%
ID Market
1 Year Return
60.3%
MERK
20.4%
ID Pharmaceuticals
22.3%
ID Market
Return vs Industry: MERK exceeded the ID Pharmaceuticals industry which returned 20.4% over the past year.
Return vs Market: MERK exceeded the ID Market which returned 22.3% over the past year.
Shareholder returns
| MERK | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.9% | 1.3% | -0.5% |
| 30 Day | 2.2% | -3.8% | -2.7% |
| 90 Day | 3.5% | -9.1% | -5.5% |
| 1 Year | 66.5%60.3% | 22.7%20.4% | 26.3%22.3% |
| 3 Year | -11.4%-46.8% | 2.3%-3.3% | 2.3%-5.4% |
| 5 Year | -25.6%-56.7% | 32.9%20.3% | 34.1%17.8% |
Long-Term Price Volatility Vs. Market
How volatile is Merck's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Merck undervalued compared to its fair value and its price relative to the market?
12.6x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: MERK (IDR3240) is trading above our estimate of fair value (IDR1111.69)
Significantly Below Fair Value: MERK is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MERK is good value based on its PE Ratio (12.5x) compared to the ID Pharmaceuticals industry average (25x).
PE vs Market: MERK is good value based on its PE Ratio (12.5x) compared to the ID market (22.4x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MERK's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MERK's PB Ratio (2.4x) is in line with the ID Pharmaceuticals industry average.
Future Growth
How is Merck forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
18.4%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Merck has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Merck performed over the past 5 years?
-25.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MERK has high quality earnings.
Growing Profit Margin: MERK became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: MERK's earnings have declined by 25.1% per year over the past 5 years.
Accelerating Growth: MERK has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: MERK has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9%).
Return on Equity
High ROE: MERK's Return on Equity (19.4%) is considered low.
Financial Health
How is Merck's financial position?
Financial Position Analysis
Short Term Liabilities: MERK's short term assets (IDR723.2B) exceed its short term liabilities (IDR298.9B).
Long Term Liabilities: MERK's short term assets (IDR723.2B) exceed its long term liabilities (IDR35.0B).
Debt to Equity History and Analysis
Debt Level: MERK is debt free.
Reducing Debt: MERK had no debt 5 years ago.
Debt Coverage: MERK has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: MERK has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is Merck current dividend yield, its reliability and sustainability?
3.98%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: MERK's dividend (4.01%) is higher than the bottom 25% of dividend payers in the ID market (1.15%).
High Dividend: MERK's dividend (4.01%) is low compared to the top 25% of dividend payers in the ID market (4.83%).
Stability and Growth of Payments
Stable Dividend: MERK's dividend payments have been volatile in the past 10 years.
Growing Dividend: MERK's dividend payments have fallen over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (50.1%), MERK's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
7.5yrs
Average management tenure
CEO
Martin Feulner (50 yo)
7.08yrs
Tenure
Mr. Martin Feulner has been the President Director of PT Merck Tbk since April 11, 2014. Mr. Feulner joined Merck in 2001. He has been an Executive Director of PT Merck Tbk since April 2012. He holds a Do...
Leadership Team
Experienced Management: MERK's management team is seasoned and experienced (7.5 years average tenure).
Board Members
Experienced Board: MERK's board of directors are considered experienced (8.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
PT Merck Tbk's company bio, employee growth, exchange listings and data sources
Key Information
- Name: PT Merck Tbk
- Ticker: MERK
- Exchange: IDX
- Founded: 1970
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: Rp1.465t
- Shares outstanding: 448.00m
- Website: https://www.merckgroup.com/id-id
Number of Employees
Location
- PT Merck Tbk
- Jl. TB Simatupang No. 8
- Pasar Rebo
- Jakarta Timur
- Jakarta Raya
- 13760
- Indonesia
Listings
Biography
PT Merck Tbk manufactures and sells pharmaceutical products in Indonesia. It operates through three segments: Biopharma, Consumer Health, and Others. The company operates in the healthcare, life science, a...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/05/10 17:29 |
| End of Day Share Price | 2021/05/10 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.